A validated in-house assay for HIV drug resistance mutation surveillance from dried blood spot specimens

被引:1
|
作者
Neufeld, Bronwyn [1 ]
Munyuza, Chantal [1 ]
Reimer, Alexandria [1 ]
Capina, Rupert [1 ]
Lee, Emma R. [1 ]
Becker, Marissa [2 ,3 ]
Sandstrom, Paul [1 ]
Ji, Hezhao [1 ,2 ]
Cholette, Francois
机构
[1] Natl Sexually Transmitted & Blood Borne Infect Lab, Natl Microbiol Lab, Publ Hlth Agcy Canada, JC Wilt Infect Dis Res Ctr, 745 Logan Ave, Winnipeg, MB R3E 3L5, Canada
[2] Univ Manitoba, Max Rady Coll Med, Dept Med Microbiol & Infect Dis, Winnipeg, MB, Canada
[3] Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB, Canada
基金
美国国家卫生研究院;
关键词
HIV; Drug resistance; Dried blood spots; Surveillance; GENOTYPING ASSAY; VIRAL LOAD; ANTIRETROVIRAL THERAPY; REVERSE-TRANSCRIPTASE; FIELD-EVALUATION; SUBTYPE-B; GENOMES; AFRICA; PLASMA; PCR;
D O I
10.1016/j.jviromet.2024.114939
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Despite increasing scale-up of antiretroviral therapy (ART) coverage, challenges related to adherence and HIV drug resistance (HIVDR) remain. The high cost of HIVDR surveillance is a persistent challenge with implementation in resource-constrained settings. Dried blood spot (DBS) specimens have been demonstrated to be a feasible alternative to plasma or serum for HIVDR genotyping and are more suitable for lower resource settings. There is a need for affordable HIVDR genotyping assays which can amplify HIV-1 sequences from DBS specimens, particularly those with low viral loads, at a low cost. Here, we present an in-house assay capable of reliably amplifying HIV-1 protease and partial reverse transcriptase genes from DBS specimens, which covers the complete World Health Organization 2009 list of drug resistance mutations under surveillance. DBS specimens were prepared using whole blood spiked with HIV-1 at concentrations of 10,000, 5000, 1000, and 500 copies/mL (n=30 for each concentration). Specimens were tested in triplicate. A two-step approach was used consisting of cDNA synthesis followed by nested PCR. The limit of detection of the assay was calculated to be approximately 5000 (95 % CI: 3200-10,700) copies/mL for the protease gene and 3600 (95 % CI: 2200-10,000) copies/mL for reverse transcriptase. The assay was observed to be most sensitive with higher viral load specimens (97.8 % [95 % CI: 92.2-99.7]) for both protease and reverse transcriptase at 10,000 copies/mL with performance decreasing with the use of specimens with lower viral loads (46.7 % [36.1-57.5] and 60.0 % [49.1-70.2] at 500 copies/mL for protease and reverse transcriptase, respectively). Ultimately, this assay presents a promising opportunity for use in resource-constrained settings. Future work should involve validation under field conditions including sub-optimal storage conditions and preparation of DBS with fingerprick blood in order to accurately reflect real-world collection scenarios.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] A Simple Dried Blood Spot Assay for Therapeutic Drug Monitoring of Lamotrigine
    Salah AbuRuz
    Mutasim Al-Ghazawi
    Yousef Al-Hiari
    Chromatographia, 2010, 71 : 1093 - 1099
  • [22] Application of a broadly sensitive genotyping assay using dried blood spots for surveillance of HIV-1 drug resistance in PEPFAR countries
    McNulty, A.
    Diallo, K.
    Zhang, J.
    Kassim, S.
    Bennett, D.
    Aberle-Gasse, J.
    Kibuka, T.
    Nkengasong, J. N.
    Yang, C.
    ANTIVIRAL THERAPY, 2007, 12 (05) : S59 - S59
  • [23] A Simple Dried Blood Spot Assay for Therapeutic Drug Monitoring of Lamotrigine
    AbuRuz, Salah
    Al-Ghazawi, Mutasim
    Al-Hiari, Yousef
    CHROMATOGRAPHIA, 2010, 71 (11-12) : 1093 - 1099
  • [24] Fluorimetric assay with a novel substrate for quantification of galactocerebrosidase activity in dried blood spot specimens
    Ullal, Anirudh J.
    Pham, Hong
    Singh, Rajendra
    Ross, Peter
    Graham, Carrie A.
    Norton, Scott M.
    Nuffer, Miriam H.
    Burns, Debbie S.
    Eckhardt, Allen E.
    Escolar, Maria
    Bali, Deeksha
    Pamula, Vamsee K.
    PRACTICAL LABORATORY MEDICINE, 2020, 18
  • [25] Evaluation of a Novel In-house HIV-1 Genotype Drug Resistance Assay using Clinical Samples in China
    Gao, Peijie
    Yu, Fengting
    Yang, Xiaozhen
    Li, Dan
    Shi, Yalun
    Wang, Yan
    Zhang, Fujie
    CURRENT HIV RESEARCH, 2022, 20 (01) : 32 - 41
  • [26] HIV-2 Drug Resistance Genotyping from Dried Blood Spots
    Raugi, Dana N.
    Nixon, Robert S.
    Leong, Sally
    Faye, Khadim
    Diatta, Jean Phillipe
    Sall, Fatima
    Smith, Robert A.
    Sall, ElHadji Ibrahima
    Malomar, Jean Jacques
    Seydi, Moussa
    Gottlieb, Geoffrey S.
    JOURNAL OF CLINICAL MICROBIOLOGY, 2021, 59 (01)
  • [27] Dried blood spot liquid chromatography assay for therapeutic drug monitoring of metformin
    AbuRuz, S
    Millership, J
    McElnay, J
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2006, 832 (02): : 202 - 207
  • [28] Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1
    Wallis, Carole L.
    Papathanasopoulos, Maria A.
    Lakhi, Shabir
    Karita, Etienne
    Kamali, Anatoli
    Kaleebu, Pontiano
    Sanders, Eduard
    Anzala, Omu
    Bekker, Linda-Gail
    Stevens, Gwynn
    de Wit, Tobias F. Rinke
    Stevens, Wendy
    JOURNAL OF VIROLOGICAL METHODS, 2010, 163 (02) : 505 - 508
  • [29] Stability of HIV-1 Nucleic Acids in Dried Blood Spot Samples for HIV-1 Drug Resistance Genotyping
    Aitken, Susan C.
    Wallis, Carole L.
    Stevens, Wendy
    de Wit, Tobias Rinke
    Schuurman, Rob
    PLOS ONE, 2015, 10 (07):
  • [30] Dried blood spot UHPLC-MS/MS analysis of oseltamivir and oseltamivircarboxylate—a validated assay for the clinic
    Gero P. Hooff
    Roland J. W. Meesters
    Jeroen J. A. van Kampen
    Nick A. van Huizen
    Birgit Koch
    Asmar F. Y. Al Hadithy
    Teun van Gelder
    Albert D. M. E. Osterhaus
    Rob A. Gruters
    Theo M. Luider
    Analytical and Bioanalytical Chemistry, 2011, 400 : 3473 - 3479